Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Drug discovery in the ubiquitin-proteasome system.

Author information

Affiliations

  • 1. Department of Pathology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.
      Authors
    • Nalepa G 1
    (1 author)

ORCIDs linked to this article

Nature reviews. Drug Discovery, 01 Jul 2006, 5(7):596-613
https://doi.org/10.1038/nrd2056 PMID: 16816840 

Review

Abstract 

Regulated protein turnover via the ubiquitin-proteasome system (UPS) underlies a wide variety of signalling pathways, from cell-cycle control and transcription to development. Recent evidence that pharmacological inhibition of the proteasome can be efficacious in the treatment of human cancers has set the stage for attempts to selectively inhibit the activities of disease-specific components of the UPS. Here, we review recent advances linking UPS components with specific human diseases, most prominently cancer and neurodegenerative disorders, and emphasize potential sites of therapeutic intervention along the regulated protein-degradation pathway.

Full text links 

Read article at publisher's site: https://doi.org/10.1038/nrd2056

References 

Articles referenced by this article (169)

Show 10 more references (10 of 169)

Citations & impact 

Impact metrics

360
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/3860120
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/3860120

Article citations

Go to all (360) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

NIA NIH HHS (1)